NATCO Pharma Future Growth
Future criteria checks 0/6
NATCO Pharma's earnings are forecast to decline at 1.4% per annum while its annual revenue is expected to grow at 4.6% per year. EPS is expected to decline by 1.4% per annum. Return on equity is forecast to be 6.9% in 3 years.
Key information
-1.4%
Earnings growth rate
-1.4%
EPS growth rate
| Pharmaceuticals earnings growth | 17.1% |
| Revenue growth rate | 4.6% |
| Future return on equity | 6.9% |
| Analyst coverage | Good |
| Last updated | 30 May 2024 |
Recent future growth updates
NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models
May 30
NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next
Feb 18Recent updates
NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings Are Not Doing Enough For Some Investors
Jun 14NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models
May 30Calculating The Fair Value Of NATCO Pharma Limited (NSE:NATCOPHARM)
May 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Apr 03NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25
Feb 21NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next
Feb 18NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement
Feb 17Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jan 25An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued
Jan 09Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?
Dec 13An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued
Sep 30Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today
Sep 12NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year
Aug 12Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?
Jul 16NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate
Apr 20Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?
Dec 20NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's
Aug 12Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?
Jun 23Broker Revenue Forecasts For NATCO Pharma Limited (NSE:NATCOPHARM) Are Surging Higher
Jun 02NATCO Pharma's (NSE:NATCOPHARM) Shareholders Will Receive A Bigger Dividend Than Last Year
Feb 22Estimating The Intrinsic Value Of NATCO Pharma Limited (NSE:NATCOPHARM)
Feb 16Here's Why NATCO Pharma (NSE:NATCOPHARM) Has A Meaningful Debt Burden
Nov 30Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2027 | 34,142 | 6,476 | 10,836 | 15,393 | 3 |
| 3/31/2026 | 53,279 | 18,229 | 13,535 | 16,750 | 12 |
| 3/31/2025 | 47,616 | 17,337 | 9,994 | 14,022 | 9 |
| 3/31/2024 | 41,269 | 13,883 | 8,529 | 12,116 | N/A |
| 12/31/2023 | 38,298 | 12,778 | N/A | N/A | N/A |
| 9/30/2023 | 35,637 | 11,274 | 5,230 | 7,477 | N/A |
| 6/30/2023 | 29,630 | 8,152 | N/A | N/A | N/A |
| 3/31/2023 | 27,085 | 7,153 | 6,435 | 8,491 | N/A |
| 12/31/2022 | 24,074 | 3,890 | N/A | N/A | N/A |
| 9/30/2022 | 24,754 | 4,071 | 5,575 | 8,302 | N/A |
| 6/30/2022 | 24,191 | 4,154 | N/A | N/A | N/A |
| 3/31/2022 | 19,462 | 1,700 | -1,962 | 465 | N/A |
| 12/31/2021 | 16,833 | 2,735 | N/A | N/A | N/A |
| 9/30/2021 | 14,780 | 2,558 | -2,457 | 230 | N/A |
| 6/30/2021 | 18,990 | 3,931 | N/A | N/A | N/A |
| 3/31/2021 | 20,561 | 4,409 | 465 | 2,988 | N/A |
| 12/31/2020 | 21,756 | 4,820 | N/A | N/A | N/A |
| 9/30/2020 | 23,026 | 5,238 | 1,554 | 4,466 | N/A |
| 6/30/2020 | 19,861 | 4,404 | N/A | N/A | N/A |
| 3/31/2020 | 19,150 | 4,608 | 587 | 4,173 | N/A |
| 12/31/2019 | 19,159 | 4,875 | N/A | N/A | N/A |
| 9/30/2019 | 19,904 | 5,425 | -2,200 | 1,600 | N/A |
| 6/30/2019 | 20,482 | 6,060 | N/A | N/A | N/A |
| 3/31/2019 | 20,945 | 6,444 | 2,071 | 6,688 | N/A |
| 12/31/2018 | 24,066 | 8,235 | N/A | N/A | N/A |
| 9/30/2018 | 24,121 | 8,815 | N/A | N/A | N/A |
| 6/30/2018 | 22,953 | 7,838 | N/A | N/A | N/A |
| 3/31/2018 | 21,848 | 6,962 | 393 | 4,636 | N/A |
| 12/31/2017 | 19,817 | 5,730 | N/A | N/A | N/A |
| 9/30/2017 | 20,895 | 5,506 | N/A | 4,985 | N/A |
| 6/30/2017 | 21,679 | 5,323 | N/A | N/A | N/A |
| 3/31/2017 | 20,202 | 4,860 | N/A | 3,458 | N/A |
| 12/31/2016 | 17,697 | 3,680 | N/A | N/A | N/A |
| 9/30/2016 | 13,692 | 2,113 | N/A | N/A | N/A |
| 6/30/2016 | 12,431 | 1,748 | N/A | N/A | N/A |
| 3/31/2016 | 10,423 | 1,549 | N/A | 1,122 | N/A |
| 12/31/2015 | 9,355 | 1,494 | N/A | N/A | N/A |
| 9/30/2015 | 8,549 | 1,266 | N/A | N/A | N/A |
| 6/30/2015 | 8,390 | 1,294 | N/A | N/A | N/A |
| 3/31/2015 | 7,305 | 1,293 | N/A | 927 | N/A |
| 12/31/2014 | 8,089 | 1,042 | N/A | N/A | N/A |
| 9/30/2014 | 8,108 | 1,199 | N/A | N/A | N/A |
| 6/30/2014 | 7,648 | 1,144 | N/A | N/A | N/A |
| 3/31/2014 | 7,389 | 1,027 | N/A | 1,440 | N/A |
| 12/31/2013 | 7,078 | 900 | N/A | N/A | N/A |
| 9/30/2013 | 6,796 | 826 | N/A | N/A | N/A |
| 6/30/2013 | 6,906 | 766 | N/A | N/A | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NATCOPHARM's earnings are forecast to decline over the next 3 years (-1.4% per year).
Earnings vs Market: NATCOPHARM's earnings are forecast to decline over the next 3 years (-1.4% per year).
High Growth Earnings: NATCOPHARM's earnings are forecast to decline over the next 3 years.
Revenue vs Market: NATCOPHARM's revenue (4.6% per year) is forecast to grow slower than the Indian market (9.6% per year).
High Growth Revenue: NATCOPHARM's revenue (4.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NATCOPHARM's Return on Equity is forecast to be low in 3 years time (6.9%).